ꢀꢀꢀꢁ
6ꢀ ꢀL. An et al.: Metal-free oxidative coupling of aminopyridines with nitroolefins
(100 MHz, CDCl3): δ ꢀ=ꢀ 149.7, 145.2, 132.3, 130.1, 130.0, 129.9, 4.1.14 2-(4-Bromophenyl)-8-methyl-3-
128.7, 128.1, 125.9, 116.5, 77.4, 77.1, 76.7, 16.6 ppm. – HRMS
nitroimidazo[1,2-a]pyridine (3n)
[(+)-ESI]: m/z ꢀ=ꢀ 254.0933 (calcd. 254.0930 for C14H12N3O2,
+
[M+H] ).
1H NMR (400 MHz, CDCl3): δ ꢀ=ꢀ 9.37 (d, J ꢀ=ꢀ 6.9 Hz, 1H), 7.82
(d, J ꢀ=ꢀ 8.4 Hz, 1H), 7.65 (d, J ꢀ=ꢀ 8.4 Hz, 1H), 7.47 (d, J ꢀ=ꢀ 7.0
Hz, 1H), 7.20 (t, J ꢀ=ꢀ 7.0 Hz, 1H), 2.73 (s, 2H) ppm. – 13C NMR
(100 MHz, CDCl3): δ ꢀ=ꢀ 148.5, 145.2, 131.8, 131.4, 131.1, 130.1,
128.7, 125.9, 124.6, 116.7, 16.6 ppm. – HRMS [(+)-ESI]: m/z ꢀ=ꢀ
4.1.10 2-(4-Methoxyphenyl)-8-methyl-3-
nitroimidazo[1,2-a]pyridine (3j)
+
332.0016 (calcd. 332.0029 for C14H11BrN3O2, [M+H] ).
1H NMR (400 MHz, CDCl3): δ ꢀ=ꢀ 9.32 (d, J ꢀ=ꢀ 6.0 Hz, 1H),
7.94 (d, J ꢀ=ꢀ 8.6 Hz, 2H), 7.40 (d, J ꢀ=ꢀ 6.9 Hz, 1H), 7.11 (t, J ꢀ=ꢀ
6.9 Hz, 1H), 7.00 (d, J ꢀ=ꢀ 8.4 Hz, 2H), 3.87 (s, 3H), 2.69 (s,
3H) ppm. – 13C NMR (100 MHz, CDCl3): δ ꢀ=ꢀ 161.22, 149.59,
145.21, 131.89, 129.85, 128.32, 125.97, 124.48, 116.11, 113.59,
55.37, 16.52 ppm. – HRMS [(+)-ESI]: m/z ꢀ=ꢀ 306.0857 (calcd.
4.1.15 2-(4-Chlorophenyl)-8-methyl-3-
nitroimidazo[1,2-a]pyridine (3o)
1H NMR (400 MHz, CDCl3): δ ꢀ=ꢀ 9.36 (d, J ꢀ=ꢀ 6.9 Hz, 1H),
7.88 (d, J ꢀ=ꢀ 8.4 Hz, 2H), 7.47 (t, J ꢀ=ꢀ 7.2 Hz, 3H), 7.19 (t, J ꢀ=ꢀ
7.0 Hz, 1H), 2.72 (s, 3H) ppm. – 13C NMR (100 MHz, CDCl3):
δ ꢀ=ꢀ 148.5, 145.2, 136.2, 131.6, 130.7, 130.1, 128.7, 128.4, 125.9,
116.7, 16.6 ppm. – HRMS [(+)-ESI]: m/z ꢀ=ꢀ 288.0530 (calcd.
+
306.0855 for C15H13N3O3Na, [M+Na] ).
4.1.11 8-Methyl-3-nitro-2-p-tolylimidazo[1,2-a]pyridine
(3k) [31]
+
288.0540 for C14H11ClN3O2, [M+H] ).
1H NMR (400 MHz, CDCl3): δ ꢀ=ꢀ 9.33 (d, J ꢀ=ꢀ 6.9 Hz, 1H),
7.83 (d, J ꢀ=ꢀ 7.9 Hz, 2H), 7.40 (d, J ꢀ=ꢀ 7.0 Hz, 1H), 7.30 (d, J ꢀ=ꢀ
7.8 Hz, 2H), 7.13 (t, J ꢀ=ꢀ 7.0 Hz, 1H), 2.70 (s, 3H), 2.43 (s, 3H)
ppm. – 13C NMR (100 MHz, CDCl3): δ ꢀ=ꢀ 149.8, 145.2, 140.3,
130.1, 129.8, 129.3, 128.8, 128.5, 125.9, 116.3, 21.5, 16.6 ppm.
– HRMS [(+)-ESI]: m/z ꢀ=ꢀ 268.1082 (calcd. 268.1086 for
5 Supporting Information
General experimental information, spectroscopic data,
and spectra of compounds 3a–3o are summarized as
Supporting Information available online (DOI: 10.1515/
znb-2015-0171).
+
C15H14N3O2, [M+H] ).
4.1.12 2-(Benzo[d][1,3]dioxol-5-yl)-8-methyl-3-
nitroimidazo[1,2-a]pyridine (3l)
Acknowledgments: We are grateful to the National
Natural Science Foundation of China (21375044), Uni-
versity Natural Science Foundation of Jiangsu Province
(12KJD150002), and Administration of Science & Technol-
ogy of Huaian City (HAG2013011) for financial support.
1H NMR (400 MHz, CDCl3): δ ꢀ=ꢀ 9.35 (d, J ꢀ=ꢀ 6.9 Hz, 1H), 7.51–
7.58 (dd, J ꢀ=ꢀ 6,4 Hz, 1.6 Hz, 1H), 7.43(d, J ꢀ=ꢀ 1.6 Hz, 2H), 7.15
(t, J ꢀ=ꢀ 7.1 Hz, 1H), 6.93 (d, J ꢀ=ꢀ 8.1 Hz, 1H), 6.04 (s, 1H), 2.71
(s, 3H) ppm. – 13C NMR (100 MHz, CDCl3): δ ꢀ=ꢀ 149.4, 149.3,
147.5, 145.1, 129.9, 128.4, 125.9, 125.1, 116.3, 110.6, 108.2,
101.5, 16.6 ppm. – HRMS [(+)-ESI]: m/z ꢀ=ꢀ 320.0626 (calcd.
References
+
320.0647 for C15H11N3O4Na, [M+Na] ).
[1] Z. H. Shao, H. B. Zhang, Chem. Soc. Rev. 2012, 41, 560.
[2] C. F. Lee, Y. C. Liu, S. S. Badsara, Chem.-Asian J. 2014, 9, 706.
[3] Q. Xiao, Y. Zhang, J. B. Wang, Acc. Chem. Res. 2013, 46, 236.
[4] A. Bhunia, S. R. Yetra, A. T. Biju, Chem. Soc. Rev. 2012, 41, 3140.
[5] J. J. Mousseau, A. B. Charette, Acc. Chem. Res. 2013, 46, 412.
[6] R. A. D. Arancon, C. S. K. Lin, C. Vargas, R. Luque, Org. Biomol.
Chem. 2014, 12, 10.
4.1.13 2-(2-Fluorophenyl)-8-methyl-3-
nitroimidazo[1,2-a]pyridine (3m)
1H NMR (400 MHz, CDCl3): δ ꢀ=ꢀ 9.36 (d, J ꢀ=ꢀ 6.8 Hz, 1H), 7.66–
7.70 (m, 1H), 7.45–7.53 (m, 2H), 7.28–7.32 (m, 1H), 7.18–7.23
(m, 2H), 2.74 (s, 3H) ppm. – 13C NMR (100 MHz, CDCl3):
δ ꢀ=ꢀ 161.9, 159.4, 145.3, 143.8, 131.8, 131.7, 131.2, 131.2, 129.7,
128.7, 125.5, 124.2, 124.2, 121.2, 121.1, 116.6, 115.9, 115.6, 16.7
ppm. – HRMS [(+)-ESI]: m/z ꢀ=ꢀ 294.0651 (calcd. 294.0655
[7] R. Samanta, K. Matcha, A. P. Antonchick, Eur. J. Org. Chem.
2013, 2013, 5769.
[8] F. Couty, G. Evano, in Comprehensive Heterocyclic Chemistry III
(Eds. A. R. Katritzky, C. A. Ramsden, E. F. V. Scriven,
R. J. K. Taylor), Elsevier, Oxford, UK, 2008, p. 409.
[9] C. Enguehard-Gueiffier, A. Gueiffier, Mini-Rev. Med. Chem.
Oxford, UK, 2007, 7, 888.
+
for C14H10FN3O2Na, [M+Na] ).
Brought to you by | Dalhousie University
Authenticated
Download Date | 2/1/16 1:04 PM